Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All four claims align with the provided label excerpts where applicable; specifically, indications match Sections 1.1 and 1.2. The brand-name mapping and manufacturer information are not contained in the provided label excerpts, but they are not contradicted by them.
Category Scores
Accurate Statements
Vivitrol is used in the treatment of alcohol dependence.
Section 1.1: "VIVITROL is indicated for the treatment of alcohol dependence..."
Vivitrol is used in the treatment of opioid dependence.
Section 1.2: VIVITROL is indicated "for the prevention of relapse to opioid dependence, following opioid detoxification."
Unsupported Statements
Vivitrol is the brand name for injectable naltrexone.
Brand-name-to-active-ingredient mapping is not explicitly present in the provided label excerpts.
Alkermes, Inc. is the manufacturer of Vivitrol.
Manufacturer information is not present in the provided label excerpts.
Contradictions
Low
AI Statement
Vivitrol is used in the treatment of opioid dependence.
Label Reference
Section 1.2 indicates prevention of relapse following opioid detoxification (not general treatment phrased without that context).
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Claims evaluated concern indications only. The opioid-dependence claim is broadly phrased and does not include the label’s key context (relapse prevention following detoxification), but no dosing/safety instructions or contraindications were provided incorrectly.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The opioid-dependence indication is stated without the label’s qualifying wording (prevention of relapse after opioid detoxification).
Suggested Improvement
Rephrase to match Section 1.2: "indicated for the prevention of relapse to opioid dependence, following opioid detoxification."